Leerink Partnrs Has Negative Outlook of MAZE Q1 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Investment analysts at Leerink Partnrs cut their Q1 2025 earnings per share estimates for shares of Maze Therapeutics in a research note issued on Monday, March 31st. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.64) per share for the quarter, down from their previous forecast of ($0.58). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($2.55) EPS.

Other equities analysts have also issued reports about the company. Guggenheim restated a “buy” rating and set a $19.00 target price on shares of Maze Therapeutics in a report on Wednesday. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Leerink Partners initiated coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an “outperform” rating and a $28.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 price target on the stock. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Maze Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.67.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $10.37 on Thursday. Maze Therapeutics has a 1-year low of $9.49 and a 1-year high of $17.00.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Monday, March 31st. The company reported ($18.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($7.60) by ($10.72).

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.